Interventional psychiatry (Part 2)

Neuromodulation may be an effective option for some patients with difficult-to-treat conditions

While most psychiatric treatments have traditionally consisted of pharmacotherapy with oral medications, a better understanding of the pathophysiology underlying many mental illnesses has led to the recent increased use of treatments that require specialized administration and the creation of a subspecialty called interventional psychiatry. In Part 1 of this 2-part article ("Interventional psychiatry [Part 1], CURRENT PSYCHIATRY, May 2023, p. 24-35, doi:10.12788/cp.0356), we highlighted parenteral medications used in psychiatry, as well as stellate ganglion blocks, glabellar botulinum toxin injections, and trigger point injections. In Part 2, we review interventional approaches that involve therapeutic neuromodulation and acupuncture.

Neuromodulation treatments

Neuromodulation—the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation, to specific neurologic sites—is an increasingly common approach to treating a variety of psychiatric conditions. The use of some form of neuromodulation as a medical treatment has a long history (Box, page 28). Modern electric neuromodulation began in the 1930s with electroconvulsive therapy (ECT). The 1960s saw the introduction of deep brain stimulation (DBS), spinal cord stimulation, and later, vagus

Disclosures

Dr. Farooqui is a speaker for AbbVie and BioXcel. Dr. El-Mallakh is a speaker for Axsome, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Myriad, Noven, Otsuka, and Teva, and has received research support from Sunovion. Dr. El-Mallakh is CURRENT PSYCHIATRY’s Section Editor, Clinical Neuroscience. Dr. Arbuck reports no financial relationships with any companies whose products are mentioned in this article, or with manufacturers or competing products.

doi: 10.12788/cp.0356
Interventional psychiatry

The origins of neuromodulation

The depth and breadth of human anatomical knowledge has evolved over millennia. The time frame “thousands of years” may appear to be an overstatement, but evidence exists for successful therapeutic limb amputation as early as 31,000 years ago. 

This suggests that human knowledge of bone, muscle, and blood supply was developed much earlier than initially believed. Early Homo sapiens were altering the body—regulating or adjusting it—to serve a purpose; in this case, the purpose was survival. 

In 46 AD, electrical modulation was introduced by Scribonius Largus, a physician in court of the emperor Tiberius, who used “torpedoes” (most likely electric eels) to treat headaches and pain from arthritis. Loosely, these early clinicians were modulating human function.

In the late 1800s, electrotherapeutics was a growing branch of medicine, with its own national organization—the American Electro-Therapeutic Association. In that era, electricity was novel, powerful, and seen as “the future.” Because such novel therapeutics were offered by both mainstream and dubious sources, “many of these products were marketed with the promise of curing everything from cancer to headaches.”

Modern electric neuromodulation began in the 1930s with electroconvulsive therapy, followed by deep brain stimulation and spinal cord stimulation in the 1960s. Target-specific noninvasive brain stimulation became possible when Anthony Barker’s team developed the first device that permitted transcranial magnetic stimulation in 1985.

Electroconvulsive therapy is associated with significant improvements in depressive symptoms

Electroconvulsive therapy is associated with significant improvements in depressive symptoms. The depth and breadth of human anatomical knowledge has evolved over millennia. The time frame “thousands of years” may appear to be an overstatement, but evidence exists for successful therapeutic limb amputation as early as 31,000 years ago. This suggests that human knowledge of bone, muscle, and blood supply was developed much earlier than initially believed. Early Homo sapiens were altering the body—regulating or adjusting it—to serve a purpose; in this case, the purpose was survival.

In 46 AD, electrical modulation was introduced by Scribonius Largus, a physician in court of the emperor Tiberius, who used “torpedoes” (most likely electric eels) to treat headaches and pain from arthritis. Loosely, these early clinicians were modulating human function.

In the late 1800s, electrotherapeutics was a growing branch of medicine, with its own national organization—the American Electro-Therapeutic Association. In that era, electricity was novel, powerful, and seen as “the future.” Because such novel therapeutics were offered by both mainstream and dubious sources, “many of these products were marketed with the promise of curing everything from cancer to headaches.”

Modern electric neuromodulation began in the 1930s with electroconvulsive therapy, followed by deep brain stimulation and spinal cord stimulation in the 1960s. Target-specific noninvasive brain stimulation became possible when Anthony Barker’s team developed the first device that permitted transcranial magnetic stimulation in 1985.

In electroconvulsive therapy (ECT), electric current is applied to the brain to induce a self-limiting seizure. It is the oldest and best-known interventional psychiatric treatment. ECT can also be considered one of the first treatments specifically developed to address pathophysiologic changes. In 1934, Ladislas J. Meduna, who had observed in neuropathologic studies that microglia were more numerous in patients with epilepsy compared with patients with schizophrenia, injected a patient who had been hospitalized with catatonia for 4 years with camphor, a proconvulsant. After 5 seizures, the patient began to recover. The therapeutic use of electricity was subsequently developed and optimized in animal models, and first used on human patients in Italy in 1939 and in the United States in 1940. The link between psychiatric illness and microglia, which was initially observed nearly a century ago, is making a comeback, as excessive microglial activation has been demonstrated in animal and human models of depression.

Administering ECT requires specialized equipment, anesthesia, physician training, and nursing observation. ECT also has a negative public image. All of these factors conspire to reduce the availability of ECT. Despite this, approximately 100,000 patients in the United States and >1 million worldwide receive ECT each year. Patients generally require 6 to 12 ECT treatments to achieve sufficient response and may require additional maintenance treatments.

Although ECT is used to treat psychiatric illnesses ranging from mood disorders to psychotic disorders and catatonia, it is mainly employed to treat people with severe treatment-resistant depression (TRD). ECT is associated with significant improvements in depressive symptoms and improvements in quality of life. It is superior to other treatments for TRD, such as ketamine, though a recent study did not show IV ketamine inferiority. ECT is also used to treat other neuropsychiatric disorders, such as Parkinson disease.

Clinicians have explored alternate methods of inducing therapeutic seizures.
Magnetic seizure therapy (MST) utilizes a modified magnetic stimulation device to deliver a higher energy in such a way to induce a generalized seizure under anesthesia. While patients receiving MST generally experience fewer adverse effects than with ECT, the procedure may be equal to or less effective than ECT.

Transcranial magnetic stimulation

In neuroimaging research, certain aberrant brain circuits have been implicated in the pathogenesis of depression. Specifically, anatomical and functional imaging suggests connections in the prefrontal cortex are involved in the depression process. In TMS, a series of magnetic pulses are administered via the scalp to stimulate neurons in areas of the brain associated with MDD. Early case reports on using TMS to stimulate the prefrontal cortex found significant improvement of symptoms in patients with depression. These promising results spurred great interest in the procedure. Over time, the dose and duration of stimulation has increased, along with FDA-approved indications. TMS was first FDA-approved for TRD. Although the primary endpoint of the initial clinical trial did not meet criteria for FDA approval, TMS did result in improvement across multiple other measures of depression. After the FDA approved the first TMS device, numerous companies began to produce TMS technology. Most of these companies manufacture devices with the figure-of-eight coil, with 1 company producing the Hesed-coil helmet.

An unintended outcome of the increased interest in TMS has been an increased understanding of brain regions involved in psychiatric illness. TMS was able to bring knowledge of mental health from synapses to circuits. Work in this area has further stratified the circuits involved in the manifestation of symptom clusters in depression. The exact taxonomy of these brain circuits has not been fully realized, but the default mode, salience, attention, cognitive control, and other circuits have been shown to be involved in specific symptom presentations. These circuits can be hyperactive, hypoactive, hyperconnected, or hypoconnected, with the aberrancies compared to normal controls resulting in symptoms of psychiatric illness.

This enhanced understanding of brain function has led to further research and development of protocols and subsequent FDA approval of TMS for OCD, anxious depression, and smoking cessation. In addition, it has allowed for a proliferation of off-label uses for TMS, including (but not limited to) tinnitus, pain, migraines, and various substance use disorders. TMS treatment for these conditions involves stimulation of specific anatomical brain regions that are thought to play a role in the pathology of the target disorder. For example, subthreshold stimulation of the motor cortex has shown some utility in managing symptoms of pain disorders and movement disorders. The ventromedial prefrontal cortex has been implicated in disorders in the OCD spectrum, stimulation of the frontal poles may help treat substance use disorders, and the auditory cortex has been a target for treating tinnitus and auditory hallucinations.

The location of stimulation for treating depression has evolved. The Talairach-Tournoux coordinate system has been used to determine the location of the dorsolateral prefrontal cortex (DLPFC) in relation to the motor cortex. This was measured to be 5 cm from the motor hotspot and subsequently became “the 5.5 cm rule,” taking skull convexity into account. The treatment paradigm for the Hesed coil also uses a measurement from the motor hotspot. Another commonly used methodology for coil placement involves using the 10 to 20 EEG coordinate system to individualize scalp landmarks. In this method, the F3 location corresponds most accurately to the DLPFC target. More recently, using fMRI-guided navigation for coil placement has been shown to lead to a significant reduction in depressive symptoms.

For depression, the initial recommended course of treatment is 6 weeks, but most improvement is seen in the first 2 to 3 weeks. Therefore, many clinicians administer an initial course of 3 weeks unless the response is inadequate, in which case a 6-week course is administered.

Clinical Point

TMS is FDA-approved for treatment-resistant depression, OCD, anxious depression, and smoking cessation.
patients require ongoing maintenance treatment, which can be weekly or monthly based on response.\textsuperscript{37} Research to determine the optimal TMS dose for treating neuropsychiatric symptoms is ongoing. Location, intensity of stimulation, and pulse are the components of stimulation. The pulse can be subdivided into frequency, pattern (single pulse, standard, burst), train (numbers of pulse groups), interval between trains, and total number of pulses per session. The Clinical TMS Society has published TMS protocols.\textsuperscript{38} The standard intensity of stimulation is 120% of the motor threshold (MT), which is defined as the amount of stimulation over the motor cortex required to produce movement in the extensor hallucis longus. Although treatment for depression traditionally utilizes rapid TMS (3,000 pulses delivered per session at a frequency of 10 Hz in 4-second trains), in controlled studies, accelerated protocols such as intermittent theta burst stimulation (iTBS; standard stimulation parameters: triplet 50 Hz bursts at 5 Hz, with an interval of 8 seconds for 600 pulses per session) have shown noninferiority.\textsuperscript{36,39} Recent research has explored fMRI-guided iTBS in an even more accelerated format. The Stanford Neuromodulation Therapy trial involved 1,800 pulses per session for 10 sessions a day for 5 days at 90% MT.\textsuperscript{36} This treatment paradigm was shown to be more effective than standard protocols and was FDA-approved in 2022. Although this specific iTBS protocol exhibited encouraging results, the need for fMRI for adequate delivery might limit its use.

**Transcranial direct current stimulation**

Therapeutic noninvasive brain stimulation technology is plausible due to the relative lack of adverse effects and ease of administration. In transcranial direct current stimulation (tDCS), a low-intensity, constant electric current is delivered to stimulate the brain via electrodes attached to the scalp. tDCS modulates spontaneous neuronal network activity\textsuperscript{40,41} and induces polarization of resting membrane potential at the neuronal level,\textsuperscript{42} though the exact mechanism is yet to be proven. \textit{N}-methyl-\textit{D}-aspartate-glutamatergic receptors are involved in inhibitory and facilitatory plasticity induced by tDCS.\textsuperscript{43} tDCS has been suggested as a treatment for various psychiatric and medical conditions. However, the small sample sizes and experimental design of published studies have limited tDCS from being clinically recommended.\textsuperscript{30} No recommendation of Level A (definite efficacy) for its use was found for any indication. Level B recommendation (probable efficacy) was proposed for fibromyalgia, MDD episode without drug resistance, and addiction/craving. Level C recommendation (possible efficacy) is proposed for chronic lower limb neuropathic pain secondary to spinal cord lesion. tDCS was found to be probably ineffective as a treatment for tinnitus and drug-resistant MDD.\textsuperscript{30} Some research has suggested that tDCS targeting the DLPFC is associated with cognitive improvements in healthy individuals as well as those with schizophrenia.\textsuperscript{44} tDCS treatment remains experimental and investigational.

**Deep brain stimulation**

DBS is a neurosurgical procedure that uses electrical current to directly modulate specific areas of the CNS. In terms of accurate, site-specific anatomical targeting, there can be little doubt of the superiority of DBS. DBS involves the placement of leads into the brain parenchyma. Image guidance techniques are used for accurate placement. DBS is a mainstay for the symptomatic treatment of treatment-resistant movement disorders such as Parkinson disease, essential tremor, and some dystonic disorders. It also has been studied as a potential treatment for chronic pain, cluster headache, Huntington disease, and Tourette syndrome.

For treating depression, researched targets include the subgenual cingulate gyrus (SCG), ventral striatum, nucleus accumbens, inferior thalamic peduncle, medial forebrain bundle, and the red nucleus.\textsuperscript{45} In systematic reviews, improvement of depression is greatest when DBS targets the subgenual cingulate cortex and the medial forebrain bundle.\textsuperscript{46} The major limitation of DBS for treating depression is the invasive nature of
Deep TMS can achieve noninvasive stimulation of the SCG and may be associated with fewer risks, fewer adverse events, and less collateral damage. However, given the evolving concept of abnormal neurologic circuits in depression, as our understanding of circuitry in pathologic psychiatric processes increases, DBS may be an attractive option for personalized targeting of symptoms in some patients.

DBS may also be beneficial for severe, treatment-resistant OCD. Electrode implantation in the region of the internal capsule/ventral striatum, including the nucleus accumbens, is used; there is little difference in placement as a treatment for OCD vs for movement disorders.

A critical review of 23 trials and case reports of DBS as a treatment for OCD demonstrated a 47.7% mean reduction in score on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and a mean response percentage (minimum 35% Y-BOCS reduction) of 58.2%. Most patients regained a normal quality of life after DBS. A more rigorous review of 15 meta-analyses of DBS found that conclusions about its efficacy or comparative effectiveness cannot be drawn. Because of the nature of neurosurgery, DBS has many potential complications, including cognitive changes, headache, infection, seizures, stroke, and hardware failure.

**Vagus nerve stimulation**

VNS, in which an implanted device stimulates the left vagus nerve with electrical impulses, was FDA-approved for treating chronic TRD in 2005. It had been approved for treatment-resistant epilepsy in 1997. In patients with epilepsy, VNS was shown to improve mood independent of seizure control. VNS requires a battery-powered pacemaker device to be implanted under the skin over the anterior chest wall, and a wire tunneled to an electrode is wrapped around the left vagus nerve in the neck. The pacemaker is then programmed, monitored, and reprogrammed to optimize response.

---

**Table 1**

<table>
<thead>
<tr>
<th>Technique</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cranial electrical stimulation (self-administered)</td>
<td>FDA-approved for insomnia, depression, and anxiety</td>
</tr>
<tr>
<td>Electroconvulsive therapy</td>
<td>FDA-approved for bipolar disorder, schizophrenia, schizoaffective disorder, catatonia, and neuroleptic malignant syndrome</td>
</tr>
<tr>
<td>External trigeminal nerve stimulation (caregiver-administered)</td>
<td>FDA-cleared for attention-deficit/hyperactivity disorder</td>
</tr>
<tr>
<td>Focused ultrasound</td>
<td>FDA-approved for advanced Parkinson disease and essential tremor in patients who have not responded to medication</td>
</tr>
<tr>
<td>Low field magnetic stimulation</td>
<td>Experimental for depression and anxiety</td>
</tr>
<tr>
<td>Magnetic seizure therapy</td>
<td>Experimental as a possible cognition-sparing alternative to ECT</td>
</tr>
<tr>
<td>Near-infrared light therapy</td>
<td>Experimental for chronic joint pain, muscle injury, bone disorders, stroke, traumatic brain injury, and various other conditions, including depression and anxiety</td>
</tr>
<tr>
<td>Noninvasive vagus nerve stimulation (self-administered)</td>
<td>FDA-cleared for prevention and treatment of cluster headache and treatment of adolescent and adult migraine. Experimental for PTSD and depression</td>
</tr>
<tr>
<td>Optogenetics</td>
<td>Experimental for mood disorders, substance use disorders, Parkinson disease, OCD, and many other conditions</td>
</tr>
<tr>
<td>Transcranial magnetic stimulation</td>
<td>FDA-approved for depression, anxious depression, smoking cessation, and OCD</td>
</tr>
<tr>
<td>Transcranial photobiomodulation</td>
<td>Experimental for improving cognitive performance, dementia, depression, anxiety, and autism</td>
</tr>
</tbody>
</table>

ECT: electroconvulsive therapy; OCD: obsessive-compulsive disorder; PTSD: posttraumatic stress disorder
VNS is believed to stimulate deep brain nuclei that may play a role in depression. The onset of improvement is slow (it may take many months) but in carefully selected patients VNS can provide significant control of TRD. In addition to rare surgery-related complications such as a trauma to the vagal nerve and surrounding tissues (vocal cord paralysis, implant site infection, left facial nerve paralysis and Horner syndrome), VNS may cause hoarseness, dyspnea, and cough related to the intensity of the current output. Hypomania and mania were also reported; no suicidal behavior has been associated with VNS.

Noninvasive vagus nerve stimulation
In noninvasive vagus nerve stimulation (nVNS) or transcutaneous VNS, an external handheld device is applied to the neck overlying the course of the vagus nerve to deliver a sinusoidal alternating current. nVNS is currently FDA-approved for treating migraine headaches. It has demonstrated actions on neurophysiology and inflammation in patients with MDD. Exploratory research has found a small beneficial effect in patients with depression. A lack of adequate reproducibility prevents this treatment from being more widely recommended, although attempts to standardize the field are evolving.

Cranial electrical stimulation
Cranial electrical stimulation (CES) is an older form of electric stimulation developed in the 1970s. In CES, mild electrical pulses are delivered to the ear lobes bilaterally in an episodic fashion (usually 20 to 60 minutes once or twice daily). While CES can be considered a form of neuromodulation, it is not strictly interventional. Patients self-administer CES. The procedure has minimal effects on improving sleep, anxiety, and mood. Potential adverse effects include a tingling sensation in the ear lobes, lightheadedness, and foginess. A review and meta-analysis of CES for treating addiction by Kirsch showed a wide range of symptoms responding positively to CES treatment, although this study was not peer-reviewed. Because of the low quality of nearly all research that evaluated CES, this form of electric stimulation cannot be viewed as an accepted treatment for any of its listed indications.

Other neuromodulation techniques
In addition to the forms of neuromodulation we have already described, there are many other techniques. Several are promising but not yet ready for clinical use. Table 1 (page 31) and Table 2 summarize the neuromodulation techniques described in this article as well as several that are under development.

Acupuncture
Acupuncture is a Chinese form of medical treatment that began >3,000 years ago; there are written descriptions of it from >2,000 years ago. It is based on the belief that there are channels within the body through which the Qi (vital energy or life force) flow, and that inserting fine needles into these channels via the skin can rebalance Qi. Modern mechanistic hypotheses invoke involvement of inflammatory or pain pathways. Acupuncture frequently uses electric

<table>
<thead>
<tr>
<th>Surgical treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deep brain stimulation</strong></td>
</tr>
<tr>
<td><strong>Gamma-knife ablation</strong></td>
</tr>
<tr>
<td><strong>Vagus nerve stimulation</strong></td>
</tr>
<tr>
<td><strong>OCD</strong>: obsessive-compulsive disorder</td>
</tr>
</tbody>
</table>
stimulation (electro-acupuncture) to increase the potency of the procedure. Alternatively, in a related procedure (acupressure), pressure can replace the needle. Accreditation in acupuncture generally requires a master’s degree in traditional Chinese medicine but does not require any specific medical training. Acupuncture training courses for physicians are widely available.

All forms of acupuncture are experimental for a wide variety of mental and medical conditions. A meta-analysis found that most research of the utility of acupuncture for depression suffered from various forms of potential bias and was considered low quality. Nonetheless, active acupuncture was shown to be minimally superior to placebo acupuncture. A meta-analysis of acupuncture for preoperative anxiety and poststroke insomnia reported a similar low study quality. A study of 72 patients with primary insomnia revealed that acupuncture was more effective than sham acupuncture for most sleep measures.

Challenges and complications
Psychiatry is increasingly integrating medical tools in addition to psychological tools. Pharmacology remains a cornerstone of biological psychiatry and this will not soon change. However, nonpharmacologic psychiatric treatments such as therapeutic neuromodulation are rapidly emerging. These and novel methods of medication administration may present a challenge to psychiatrists who do not have access to medical personnel or may have forgotten general medical skills.

Our 2-part article has highlighted several interventional psychiatry tools—old and new—that may interest clinicians and benefit patients. As a rule, such treatments are reserved for the most treatment-resistant, challenging psychiatric patients, those with hard-to-treat chronic conditions, and patients who are not helped by more commonly used treatments. An additional complication is that such treatments are frequently not appropriately researched, vetted, or FDA-approved, and therefore are higher risk. Appropriate clinical judgment is always necessary, and potential benefits must be thoroughly weighed against possible adverse effects.

References

Bottom Line
Several forms of neuromodulation, including electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, deep brain stimulation, and vagus nerve stimulation, may be beneficial for patients with certain treatment-resistant psychiatric disorders, including major depressive disorder and obsessive-compulsive disorder.
Interventional psychiatry

Nonpharmacologic treatments may present a challenge to psychiatrists who do not have access to medical personnel.